Global Biologics Manufacturing Excellence across Quality, Efficiency, and CoGs

This event is now available on demand

Event Overview:

When bringing innovative therapies to patients, today’s biologics companies face increasing complexity. From meeting diverse regulatory requirements and ensuring consistent quality to managing technology transfer and global supply chains, companies face significant challenges that can delay timelines and increase costs.

This webinar explores practical strategies to overcome these hurdles. Through the lens of real-world examples, it illustrates how a robust global manufacturing network and advanced process technologies help biotechs and large pharma accelerate commercialization, ensure compliance, and deliver high-quality biologics to patients with competitive CoGs around the world.

Key Learning Objectives:

Your details are used to respond to your request. Please see our Privacy Policy.

  • Learn best practices for building globally accessible manufacturing with consistent quality and compliance.
  • Find out how advanced process technologies can boost efficiency and productivity in biologics manufacturing.
  • Discover practical approaches for accelerating technology transfer, process validation, and lifecycle management for faster market access.

Your details are used to respond to your request. Please see our Privacy Policy.

Who Should Attend:

Your details are used to respond to your request. Please see our Privacy Policy.

  • External supply management for biologics products
  • Biomanufacturing technical and quality experts

Your details are used to respond to your request. Please see our Privacy Policy.

Featured Speaker:

Your details are used to respond to your request. Please see our Privacy Policy.

Yuan Wen, PhD

Vice President,  Head of Wuxi

Marshan Site Global Manufacturing
Business Unit

Your details are used to respond to your request. Please see our Privacy Policy.

 

Dr Yuan Wen is Head of the Wuxi Mashan Site of Global Manufacturing Business Unit at WuXi Biologics, previosuly serving as Head of MFG1, MFG4, MFG20, and DP9. His teams were first in Asia to implement 4,000 L and 5,000 L single-use bioreactors for GMP and commercial manufacturing. This innovation served global biologic and vaccine products approved by FDA, EMA, NMPA, and more. Before his MFG roles, Dr Yuan Wen was responsible for cell culture process development at the Wuxi Mashan site, focusing on late-phase process development and process characterization. Dr Wen is also an experienced CMC leader who supports activities ranging from IND to commercial manufacturing.

Before joining WuXi Biologics, Dr Wen worked at Life Technologies and Thermo Fisher Scientific in the US with increasing technical and business responsibilities. He holds a BS in Bioengineering from Zhejiang University, and a PhD in Chemical and Biomolecular Engineering from Ohio State University.

Speaker’s Email: wen_yuan_017538@wuxibiologics.com


For any technical questions please contact Jorge de la Bandera: JdelaBandera@mjhlifesciences.com 


Your details are used to respond to your request. Please see our Privacy Policy.

Complete this form to enter the webcast.

Are you working in any of the following (select all that apply)?*
Does your organization have any outsourcing needs for biologics Drug Substance and/or Drug Product manufacturing services?:*
Yes, please subscribe me to BioPharm International's free e-newsletters.
Yes, please subscribe me to BioPharm International's free e-newsletters.
*Denotes required.

Your details are used to respond to your request. Please see our Privacy Policy.

Copyright © 2025 B2B Reports, All Rights Reserved.